SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant community conversation as investors speculate on a breakout from its recent consolidation phase, with sentiment fueled by bullish expectations for ecosystem growth and broader crypto market momentum. Traders are actively debating technical levels while engaging with various memecoin projects on the network, signaling high participation and a focus on long-term adoption.

Spitcoin is a community-driven cryptocurrency built on the Solana blockchain that powers a decentralized creator economy through the LimitlessFlo platform.  The project focuses on giving creators full control over their content and earnings by enabling instant monetization from day one—through tips, subscriptions, live streaming, and marketplace transactions—without the restrictions of traditional platforms like bans, algorithm suppression, or delayed payouts.  At its core, Spitcoin is about combining meme culture with real utility, creating a self-sustaining ecosystem where platform activity drives token demand, and token usage fuels platform growth.

SpitCoin

SpitCoin is gaining momentum as the community highlights its role in powering the LimitlessFlo ecosystem. Investors are actively drawing parallels between this project and other emerging crypto assets while calling for broader data integration across tracking platforms.

LCX.com is a platform that innovates capital markets by providing solutions for compliant digital assets and security tokens. It is a secure and compliant platform for buying, selling, transferring, and storing digital currency.

LCX is generating significant community conversation as investors speculate on potential regulatory breakthroughs and upcoming platform catalysts, despite ongoing volatility and frustration over stagnant price action. While long-term bulls remain focused on the project's utility and institutional positioning, others are actively questioning its market performance and long-term viability compared to sector leaders.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community highlights significant supply locks and a long-term 'buy and hold' strategy, fueling bullish sentiment around the project's dedication and brand visibility. Investors are actively sharing positive conviction, often grouping the token with other Solana-based assets and emphasizing a unified, long-term mission.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative momentum as community members debate whether the project is at a technical breakout point or continuing a long-term decline. Investors are actively discussing the ecosystem's IoT and data ownership narratives while venting frustration over stalled price performance and the lack of recent communication from leadership.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is generating significant momentum as the broader space sector attracts heavy institutional capital and speculative interest ahead of major launch milestones. The community remains focused on the company's dual-use defense and weather data analytics, debating the impact of recent government contract wins and pending financial reporting updates against the backdrop of potential industry-wide volatility.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as investors debate whether the stock has hit a bottom following a steep decline, with many in the community pointing to strong customer loyalty and potential undervaluation compared to its historical performance. The conversation is currently split between those aggressively averaging down in anticipation of a rebound and critics questioning management's ability to drive share price appreciation despite consistent business operations.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is attracting significant attention as investors view the company as a primary beneficiary of the massive energy demands driven by AI data centers and hyperscalers. Community sentiment remains focused on the company's strong domestic manufacturing moat and robust backlog, even as market volatility and analyst downgrades spark debate over the short-term impact of tariff policies and competitive pressures.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean is trending as investors focus on its pivot toward agentic AI infrastructure, with community discourse heavily influenced by strong institutional backing and a significant re-rating of its growth potential. The stock is being closely monitored for breakout setups as traders track its role in hosting high-performance AI inference workloads.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending due to heightened investor focus on its 'brownfield' data center strategy following a massive multi-year compute contract that validates its specialized infrastructure approach. Community sentiment remains polarized, with some bulls emphasizing the company's high revenue per megawatt and low debt compared to peers, while skeptical traders frequently debate the management team's transparency and the stock's recent volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcare Disruption, AI Biologics, and Wall Street Upgrades Ignite a Midday Market Surge

Healthcare innovators are pushing the markets today. $TGNT, $AGL, $ATRA, $ASBP

<ul class="summary-bullets"><li>Aspire Biopharma is expanding beyond its core biotech business and recently announced a $30 million all-cash acquisition of Dura Control Systems, a global automotive supplier.</li><li>The firm secured a $22.5 million credit facility for the acquisition and added that it does not expect to raise additional equity.</li><li>Aspire Biopharma had implemented a 1-for-40 reverse stock split on Jan. 16, 2026.</li></ul>Shares of Aspire Biopharma Holdings (ASBP) surged more than 21% on Monday, logging their biggest jump in over a month as a fresh $5 million buyback plan sparked renewed investor interest.Aprire Biopharma’s board approved a share repurchase program of up to $5 million, to be funded from existing cash and executed over time through open-market purchases or private transactions.“Aspire’s strengthened financial position provides us with significant flexibility in executing our capital allocation strategy. The Board's authorization of a $5 million share repurchase program further supports our commitment to returning value to shareholders,” said CEO Kraig Higginson.<h2 class="st-heading-2">Move Beyond Biotech</h2>Aspire Biopharma is expanding beyond its core biotech business with a <a href="https://stocktwits.com/news-articles/markets/equity/why-asbp-stock-is-surging-after-78-percent-crash/cZBIWpURICk">planned</a> $30 million all-cash acquisition of Dura Control Systems (DCS), a global automotive supplier. DCS generates over $200 million in annual revenue and more than $20 million in earnings, with a broad portfolio of parts and patents used by major automakers.To support the acquisition, it recently secured a $22.5 million credit facility and added that it does not expect to raise additional equity.Separately, Aspire is growing its consumer segment through its Buzz Bomb unit, which recently partnered with Interwest Brokerage to expand retail distribution. The product is a sublingual caffeine powder that delivers a quick energy boost without the need for traditional drinks like coffee or energy beverages.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/ASBP">ASBP</a> remained ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.One user said every dip was a buying opportunity as the stock climbs toward $2. It is currently trading around $0.3.<stembedurl>https://stocktwits.com/JOHNNY_DANGER/message/651520470</stembedurl>However, another user said the $5 million buyback looks more like a “distraction” than a “deal.”<stembedurl>https://stocktwits.com/Observenact/message/651516573</stembedurl>Aspire Biopharma implemented a 1-for-40 reverse stock split on Jan. 16, 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/poet-stock-biggest-intraday-fall-marvell-order-cancelled/cZBNt3nRePh">POET Stock On Track To Record Biggest Single-Day Fall After Disclosing Order Cancellation From Celestial AI – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

ASBP Stock Jumps 21% On Buyback Offer – Retail Believes Every Dip’s A Buying Opportunity

Aspire Biopharma’s board approved a share repurchase program of up to $5 million, which will be funded from existing cash.

Equity

<ul class="summary-bullets"><li>Aspire Biopharma also secured a commitment for a $22.5 million credit facility to help fund its planned acquisition of Dura Control Systems.</li><li>The deal is not expected to require any additional equity raise, the company said.</li><li>Aspire’s unit, Buzz Bomb Caffeine Company, recently partnered with Interwest Brokerage to expand its retail presence in the Intermountain West.</li></ul>Aspire Biopharma Holdings (ASBP) grabbed retail traders’ attention Tuesday after its shares surged more than 20% in pre-market trading, following the successful close of a $21 million private placement that lifted its shareholders’ equity above Nasdaq’s minimum listing requirement.<a href="https://stocktwits.com/symbol/ASBP">ASBP shares</a> are poised to bounce back after four straight sessions of losses that saw it plunge more than 78% and fall to a 52-week low on Monday.The company also secured a commitment for a $22.5 million credit facility to help fund its planned acquisition of Dura Control Systems (DCS). The deal is not expected to require any additional equity raise, Aspire Biopharma added.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier. Message volumes on the platform surged 1,175% over a 24-hour period and a whopping 5,000% over a seven-day period.One user expects the stock to reclaim $1. It last traded above that on April 14.<stembedurl>https://stocktwits.com/Kittu20/message/650857092</stembedurl>Another user expects range-bound trading.<stembedurl>https://stocktwits.com/momirk/message/650856886</stembedurl><h2 class="st-heading-2">Beyond Drug Delivery</h2>Last week, Aspire Biopharma signed a letter of intent to acquire DCS in an all-cash deal valued at $30 million. DCS is a global automotive supplier with over $200 million in FY2025 revenue and more than $20 million in earnings before interest, tax, depreciation, and amortization (EBITDA).DCS holds a broad portfolio of parts and patents serving major automakers. Aspire said the acquisition would help it evolve into a diversified, high-revenue business beyond its core drug delivery technology.Prior to that, Aspire’s unit, Buzz Bomb Caffeine Company, partnered with Interwest Brokerage to expand its retail presence in the Intermountain West. The unit’s Buzz Bomb is a single-serve caffeine powder taken under the tongue that delivers 50 mg of caffeine, eliminating the need for drinks like coffee or energy beverages.Year-to-date, the stock has slumped more than 93%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

ASBP Bulls Back In Control After 78% Crash: What Changed? 

The company closed a $21 million private placement that lifted its shareholders’ equity above Nasdaq’s minimum listing requirement.

ASBP Stock Back On Retail Radar After 78% Crash – Bulls Eye $1 Comeback

<ul class="summary-bullets"><li>Lucid fell more than 7.5% on Monday, extending a five-day decline to a 52-week low of $6.75 after recent financing announcements and the appointment of a new CEO.</li><li>Aspire Biopharma declined to a low of $0.22 after announcing an additional $22.5 million credit line to fund an acquisition.</li><li>Wearable Devices fell to a low of $1.10 after the company entered a warrant inducement agreement for $5 million.</li></ul>Lucid Group Inc. (LCID), Aspire Biopharma Holdings Inc. (ASBP) and Wearable Devices Ltd. (WLDS) stocks slipped to fresh intraday lows on Monday, with all three companies recording new 52-week lows.The declines came amid leadership uncertainty, financing concerns, and downward revisions to price targets from Wall Street analysts, which weighed on investor sentiment.<h2 class="st-heading-2">Lucid Drops On Financing, Leadership Concerns</h2>Shares of electric car manufacturer Lucid fell more than 7.5% on Monday, extending a five-day decline, as it fell to a 52-week low of $6.75. The drop followed recent financing decisions and the appointment of a new CEO.Last week, Lucid announced a $1.05 billion capital raise, including a pricing of its $300 million registered offering of common stock. The company also appointed Silvio Napoli as the new CEO.However, the company’s shares edged up after the market closed on Monday following Uber Technologies (UBER) saying it had <a href="https://stocktwits.com/news-articles/markets/equity/lcid-stock-pops-after-hours-as-uber-loads-up-on-more-shares/cZB46cLRIzu">raised its stake</a> in the EV company to 11.5%.Amid these announcements, the stock also garnered attention from Wall Street analysts, with TD Cowen and Baird lowering price targets on the company. TD Cowen cut Lucid’s price target to $10 from $19 and kept a ‘Hold’ rating on the shares, while Baird lowered the price target on Lucid to $12 from $14 and maintained a ‘Neutral’ rating on the shares.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LCID">LCID stock</a> remained in the ‘extremely bullish’ territory at the time of writing, amid ‘extremely high’ message volumes. LCID shares have declined more than 39% this year.<figure class="image"><img src="https://news.stocktwits-cdn.com/Lucid_png_3d11f9354f.webp" alt="Lucid.png" width="1280" height="156"></figure><h2 class="st-heading-2">Aspire Biopharma Slips On Financing Concerns</h2>ASBP stock declined for four straight days, slipping to a low of $0.22 on Monday after it announced it had closed the final tranche of a $21 million private placement and secured an additional $22.5 million credit line to fund the acquisition of Dura Control Systems.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ASBP">ASBP stock</a> improved from ‘bullish’ to the ‘extremely bullish’ territory over the past day, amid ‘extremely high’ message volumes. ASBP shares have declined more than 95% this year.<figure class="image"><img src="https://news.stocktwits-cdn.com/Aspire_png_0d0bf386ff.webp" alt="Aspire.png" width="1263" height="157"></figure><h2 class="st-heading-2">WLDS Falls On Warrant Inducement</h2>Shares of Wearable Devices Ltd. (WLDS) fell to a low of $1.10 on Monday after the company entered a warrant inducement agreement for $5 million that it said it would use for working capital requirements and other general corporate purposes.The company also <a href="https://stocktwits.com/news-articles/markets/equity/why-is-wlds-stock-soaring-today-best-gains-in-7-months/cZBdKfQRIz0">announced a collaboration</a> with Meta-Bounds Inc. to develop intuitive neural control for augmented reality glasses, although it failed to address investor concerns about dilution and funding needs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WLDS">WLDS stock</a> improved from ‘neutral’ to the ‘extremely bullish’ territory over the past day, amid ‘extremely high’ message volumes. WLDS shares have declined more than 65% this year.<figure class="image"><img src="https://news.stocktwits-cdn.com/WLDS_png_b4049d50bf.webp" alt="WLDS.png" width="1264" height="154"></figure>&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

LCID, ASBP, WLDS Stocks Hit 52-Week Lows: What Drove The Selloff?

Lucid Group Inc. (LCID), Aspire Biopharma Holdings Inc. (ASBP) and Wearable Devices Ltd. (WLDS) stocks slipped to fresh intraday lows on Monday, with all three companies recording new 52-week lows.

The declines came amid leadership uncertainty, financing concerns, and downward revisions in price targets from Wall Street analysts.

<ul class="summary-bullets"><li>LCID slid for a third straight day after TD Cowen and Baird trimmed their price targets following recent company updates and capital raises.</li><li>ABT dropped after cutting its 2026 EPS outlook to $5.38-$5.58 due to the impact of its $23 billion acquisition of Exact Sciences.</li><li>ASBP slumped after shareholders approved a reverse stock split and authorized additional equity issuance tied to preferred-stock conversion and financing deals.</li></ul>Shares of Lucid Group (LCID), Abbott Laboratories (ABT) and Aspire Biopharma Holdings (ASBP) dropped to fresh 52-week lows Thursday, bucking a broader market rally, as investors weighed softer growth prospects and dilution risks across the three companies.On Thursday,&nbsp;<a href="https://stocktwits.com/symbol/LCID">LCID</a> and&nbsp;<a href="https://stocktwits.com/symbol/ABT">ABT</a> shares each fell about 6%, while&nbsp;<a href="https://stocktwits.com/symbol/ASBP">ASBP</a> slumped 45%.<h2 class="st-heading-2">LCID Falls As Outlook Confidence Wavers</h2>LCID shares fell 6% on Thursday, extending their decline to a third straight session, after multiple Wall Street firms lowered price targets following recent company updates in a weaker auto market.&nbsp;Earlier this week, TD Cowen analyst Itay Michaeli cut the firm’s price target to $10 from $19 and maintained a ‘Hold’ rating, saying automakers appear better positioned than suppliers in the first quarter (Q1) to provide investors with outlook “reassurances and retaining guidance credibility.” The brokerage added that guide-down risk across the sector remains low.Baird also lowered its price target to $12 from $14 and kept a ‘Neutral’ rating after updating its model following the appointment of a permanent CEO and expansion of Lucid’s partnership with Uber.Investor sentiment has also remained under pressure from a recent $1.05 billion capital raise and a $300 million stock offering. The company is targeting production of 25,000 to 27,000 vehicles in 2026, but produced 5,500 vehicles and delivered 3,093 units in Q1 after deliveries were temporarily affected by a Gravity SUV seat-belt recall.<h2 class="st-heading-2">ABT Slides On Exact Sciences Impact To Bottomline</h2>ABT shares posted their worst session in nearly three months on Thursday after the company lowered its 2026 adjusted profit outlook due to the impact of its $23 billion acquisition of Exact Sciences.Abbott cut its full-year outlook and now expects adjusted earnings per share of $5.38 to $5.58, down from its earlier forecast of $5.55 to $5.8. Investors focused on softer organic growth trends, weakness in the nutrition segment and slower-than-expected momentum in diabetes and structural-heart devices, facing competition from Edwards Lifesciences.Evercore ISI lowered its price target to $120 from $134, saying organic growth came in “a tad below” expectations and base organic guidance was effectively reduced by about 50 basis points.However, Abbott said that the $23 billion acquisition of Exact Sciences is expected to contribute about $3 billion in incremental sales this year and support longer-term growth as Abbott continues to shift away from declining COVID testing revenue.<h2 class="st-heading-2">ASBP Slumps On Dilution Concerns</h2>ASBP shares remained under pressure after stockholders approved several proposals expanding the company’s flexibility to issue additional equity and restructure its capital base.At a special meeting earlier this month, investors approved a reverse stock split within a range of 1-for-5 to 1-for-500 and authorized the issuance of conversion shares tied to Series A preferred stock. Stockholders also approved additional equity issuance under an existing purchase agreement with Arena Business Solutions Global SPC II. A proposal to increase the authorized common shares from 490 million to 700 million was also approved.The company separately completed a preferred-stock financing tranche, generating about $10 million in proceeds, while converting part of its outstanding debt into equity, underscoring investor concerns around dilution risk and huge funding needs.Additionally, Aspire entered a letter of intent to acquire Dura Driver Control Systems in a $30 million deal to expand its footprint beyond drug delivery.<h2 class="st-heading-2">How Do Retail Traders Feel About LCID, ABT, ASBP?</h2>On Stocktwits, retail sentiment for LCID and ABT was ‘extremely bullish’ amid ‘extremely high’ message volume, while sentiment for ASBP was ‘bullish’ with ‘extremely high’ message volume.Over the past year, LCID shares have declined 67%, ABT is down 25%, and ASBP has plunged 99%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-outpaces-2025-gains-battery-swap-rollout-focus/cZJUf82RIx7">Nio Stock Already Outruns Last Year’s Gains — Now A Massive Battery-Swap Push Is Coming Into Spotlight</a>

In this photo illustration, the logo of Lucid Group, Inc. is displayed on a smartphone screen, with a stock market chart in the background, on May 4, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff?

LCID and ABT each fell about 6% on Thursday, while ASBP plunged 45%, bucking a broader market rally.

<ul class="summary-bullets"><li>Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial.</li><li>The firm said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets.</li><li>The company said that&nbsp;&nbsp;Early safety evaluations showed the product was well tolerated, with no adverse events reported.</li></ul>Shares of Aspire Biopharma Holdings (ASBP) shot up 32% on Wednesday after the company said it received favorable feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-investigational new drug (IND) meeting for OTASA, its high-dose sublingual (under-the-tongue) aspirin aimed at emergency treatment of suspected heart attacks.The FDA’s feedback supports a planned Section 505(b)(2) New Drug Application (NDA) submission in the second half of 2026, the company added.Based on the agency’s guidance, Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial. The study will enroll 32 healthy volunteers and compare OTASA 162 mg with the current standard of care, two chewed 81 mg aspirin tablets, by measuring inhibition of serum thromboxane B2, a marker linked to blood clotting.The pre-IND submission was supported by encouraging pilot clinical data. Aspire said OTASA demonstrated faster and higher absorption of acetylsalicylic acid compared with chewed aspirin tablets. The sublingual formulation also achieved rapid platelet inhibition, reducing thromboxane B2 levels within the first two minutes after administration. Early safety evaluations showed the product was well tolerated, with no adverse events reported.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/ASBP">ASBP</a> remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/ASBP_jpg_d2fe432dd1.webp" alt="ASBP.jpg" width="906" height="105"><figcaption>&nbsp;</figcaption></figure>Users speculated that the company could already be engaged in licensing negotiations.<stembedurl>https://stocktwits.com/juned/message/641088627</stembedurl><stembedurl>https://stocktwits.com/Pennystockmadness/message/641086670</stembedurl><h2 class="st-heading-2">Stock Price</h2>The update and the subsequent rally in stock price come at a time when the company has been dealing with listing concerns stemming from its low share price. In November, investors approved a proposal allowing the board to implement a reverse stock split at a ratio of 1-for-5 to 1-for-40, within one year if needed.The company has also secured Nasdaq approval to remain listed, contingent on meeting minimum bid price and equity requirements by late January and mid-February 2026.At present, the stock is trading near the $0.14 mark.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-falls-ahead-of-index-fund-rebalancing/cmxz3OLR420">Silver Tumbles 5% Amid Profit-Booking And&nbsp;Scheduled Reshuffling Of Commodity Index Funds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin –  Retail Expects Licensing Negotiations Soon

The FDA’s feedback supports a planned new drug application submission in the second half of 2026.

Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company was founded on February 2, 2025 and is headquartered in Estero, FL.

Aspire Biopharma Holdings Inc.

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

ASBP
Aspire Biopharma Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest ASBP News

ASBPAspire Biopharma Holdings Inc